192 related articles for article (PubMed ID: 38206277)
1. Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.
Al Sukhun S; Temin S; Barrios CH; Antone NZ; Guerra YC; Chavez-MacGregor M; Chopra R; Danso MA; Gomez HL; Homian NM; Kandil A; Kithaka B; Koczwara B; Moy B; Nakigudde G; Petracci FE; Rugo HS; El Saghir NS; Arun BK
JCO Glob Oncol; 2024 Jan; 10():e2300285. PubMed ID: 38206277
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline.
Vanderpuye VD; Clemenceau JRV; Temin S; Aziz Z; Burke WM; Cevallos NL; Chuang LT; Colgan TJ; Del Carmen MG; Fujiwara K; Kohn EC; Gonzáles Nogales JE; Konney TO; Mukhopadhyay A; Paudel BD; Tóth I; Wilailak S; Ghebre RG
JCO Glob Oncol; 2021 Jun; 7():1032-1066. PubMed ID: 34185571
[TBL] [Abstract][Full Text] [Related]
4. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Burstein HJ; Somerfield MR; Barton DL; Dorris A; Fallowfield LJ; Jain D; Johnston SRD; Korde LA; Litton JK; Macrae ER; Peterson LL; Vikas P; Yung RL; Rugo HS
J Clin Oncol; 2021 Dec; 39(35):3959-3977. PubMed ID: 34324367
[TBL] [Abstract][Full Text] [Related]
5. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
Giordano SH; Franzoi MAB; Temin S; Anders CK; Chandarlapaty S; Crews JR; Kirshner JJ; Krop IE; Lin NU; Morikawa A; Patt DA; Perlmutter J; Ramakrishna N; Davidson NE
J Clin Oncol; 2022 Aug; 40(23):2612-2635. PubMed ID: 35640077
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline.
Costas-Chavarri A; Nandakumar G; Temin S; Lopes G; Cervantes A; Cruz Correa M; Engineer R; Hamashima C; Ho GF; Huitzil FD; Malekzadeh Moghani M; Sharara AI; Stern MC; Teh C; Vázquez Manjarrez SE; Verjee A; Yantiss R; Shah MA
J Glob Oncol; 2019 Feb; 5():1-19. PubMed ID: 30802158
[TBL] [Abstract][Full Text] [Related]
7. Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.
Jeronimo J; Castle PE; Temin S; Denny L; Gupta V; Kim JJ; Luciani S; Murokora D; Ngoma T; Qiao Y; Quinn M; Sankaranarayanan R; Sasieni P; Schmeler KM; Shastri SS
J Glob Oncol; 2017 Oct; 3(5):635-657. PubMed ID: 29094101
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
Moinard-Butot F; Saint-Martin C; Pflumio C; Carton M; Jacot W; Cottu PH; Diéras V; Dalenc F; Goncalves A; Debled M; Patsouris A; Mouret-Reynier MA; Vanlemmens L; Leheurteur M; Emile G; Ferrero JM; Desmoulins I; Uwer L; Eymard JC; Cheaib B; Courtinard C; Bachelot T; Chevrot M; Petit T
Breast; 2022 Jun; 63():54-60. PubMed ID: 35299035
[TBL] [Abstract][Full Text] [Related]
10. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline.
Chuang LT; Temin S; Camacho R; Dueñas-Gonzalez A; Feldman S; Gultekin M; Gupta V; Horton S; Jacob G; Kidd EA; Lishimpi K; Nakisige C; Nam JH; Ngan HYS; Small W; Thomas G; Berek JS
J Glob Oncol; 2016 Oct; 2(5):311-340. PubMed ID: 28717717
[TBL] [Abstract][Full Text] [Related]
11. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
12. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer.
Ramagopalan SV; Pisoni R; Zenin A; Rathore LS; Ray J; Sammon C
J Comp Eff Res; 2021 May; 10(7):595-602. PubMed ID: 33095031
[TBL] [Abstract][Full Text] [Related]
14. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2018 Mar; 36(8):741-748. PubMed ID: 29244528
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
16. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
17. Palliative Care in the Global Setting: ASCO Resource-Stratified Practice Guideline.
Osman H; Shrestha S; Temin S; Ali ZV; Corvera RA; Ddungu HD; De Lima L; Del Pilar Estevez-Diz M; Ferris FD; Gafer N; Gupta HK; Horton S; Jacob G; Jia R; Lu FL; Mosoiu D; Puchalski C; Seigel C; Soyannwo O; Cleary JF
J Glob Oncol; 2018 Jul; 4():1-24. PubMed ID: 30085844
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
Dormann C
Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
20. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]